Health Product InfoWatch, December 2025
Content: Safety brief: Bruton’s tyrosine kinase (BTK) inhibitors and the risk of serious hepatotoxicity; Notice of authorization with conditions: Lyvdelzi (seladelpar)
Monthly update to the list of new safety and effectiveness reviews for health products
The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between October 1 and 31, 2025. The next update is scheduled for January 2026.
Monthly Update to the Canada Vigilance adverse reaction online database
The data presented in the Canada Vigilance Adverse Reaction Online Database has been updated and now includes information received by Health Canada up to August 31, 2025. The next update of data is scheduled for early January, 2026.
Health Product InfoWatch, November 2025
Content: Product monograph update: Braftovi (encorafenib); Notice of authorization with conditions: Jaypirca (pirtobrutinib); Notice of authorization with conditions: Leqembi (lecanemab)
Monthly update to the list of new safety and effectiveness reviews for health products
The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between September 1 and 30, 2025. The next update is scheduled for December 2025.
Health Promotion and Chronic Disease Prevention in Canada, Vol 45, No 11/12, November/December 2025
Mapping social determinants of cognitive health in Canada: a scoping review; Utilization of silver diamine fluoride by dentists in Canada: a review of the Non-Insured Health Benefits Dental Claims database
Health Promotion and Chronic Disease Prevention in Canada, Vol 45, No 9, September 2025
The relationship between COVID-19 and opioid-related emergency department visits in Alberta, Canada: an interrupted time series analysis; Supervised consumption sites and population-level overdose mortality: a systematic review of recent evidence, 20162024; Food-based interventions to mitigate household food insecurity in Canada: a systematic review
Health Canada and the Public Health Agency of Canada’s report on red tape reduction
Health Canada and the Public Health Agency of Canada have conducted a broad review of regulations and program administration to identify outdated, inefficient or duplicate regulations that hinder economic growth and create unnecessary burden for businesses and people in Canada.
Volume 51-8, August 2025: Antiviral Therapy
Read about: Real-time hospital surveillance system for RSV, implementation of the COVID-19 antiviral therapy across Canada, safety monitoring of Imvamune vaccine during mpox outbreak
Perinatal Care in Northern, Rural and Remote Communities
Continue reading